123 related articles for article (PubMed ID: 15266017)
1. Strategies for inhibition of MDR1 gene expression.
Xu D; Kang H; Fisher M; Juliano RL
Mol Pharmacol; 2004 Aug; 66(2):268-75. PubMed ID: 15266017
[TBL] [Abstract][Full Text] [Related]
2. Modulating multidrug resistance gene in leukaemia cells by short interfering RNA.
Lim MN; Lau NS; Chang KM; Leong CF; Zakaria Z
Singapore Med J; 2007 Oct; 48(10):932-8. PubMed ID: 17909680
[TBL] [Abstract][Full Text] [Related]
3. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.
Gan HZ; Zhang GZ; Zhao JS; Zhang FC; Bu LS; Yang SJ; Piao SL; Du ZW; Gao S; Zheng DM
Chin Med J (Engl); 2005 Jun; 118(11):893-902. PubMed ID: 15978189
[TBL] [Abstract][Full Text] [Related]
4. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
5. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
Kaszubiak A; Holm PS; Lage H
Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700
[TBL] [Abstract][Full Text] [Related]
6. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1.
Yagüe E; Higgins CF; Raguz S
Gene Ther; 2004 Jul; 11(14):1170-4. PubMed ID: 15164094
[TBL] [Abstract][Full Text] [Related]
7. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells.
Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY
Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879
[TBL] [Abstract][Full Text] [Related]
8. Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs.
Stierlé V; Laigle A; Jollès B
Biochem Pharmacol; 2005 Nov; 70(10):1424-30. PubMed ID: 16214115
[TBL] [Abstract][Full Text] [Related]
9. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator.
Xu D; Ye D; Fisher M; Juliano RL
J Pharmacol Exp Ther; 2002 Sep; 302(3):963-71. PubMed ID: 12183653
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.
Marthinet E; Divita G; Bernaud J; Rigal D; Baggetto LG
Gene Ther; 2000 Jul; 7(14):1224-33. PubMed ID: 10918491
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
13. Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1.
Kaszubiak A; Kupstat A; Müller U; Hausmann R; Holm PS; Lage H
Biochem Biophys Res Commun; 2007 May; 357(1):295-301. PubMed ID: 17418094
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides.
Alahari SK; Dean NM; Fisher MH; Delong R; Manoharan M; Tivel KL; Juliano RL
Mol Pharmacol; 1996 Oct; 50(4):808-19. PubMed ID: 8863825
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the efficiency of a siRNA directed against MDR1 expression in MCF7-R cells when combined with a second siRNA.
Stierlé V; Laigle A; Jollès B
Biochimie; 2007 Aug; 89(8):1033-6. PubMed ID: 17459558
[TBL] [Abstract][Full Text] [Related]
16. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
Pichler A; Zelcer N; Prior JL; Kuil AJ; Piwnica-Worms D
Clin Cancer Res; 2005 Jun; 11(12):4487-94. PubMed ID: 15958634
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
18. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression.
Alahari SK; DeLong R; Fisher MH; Dean NM; Viliet P; Juliano RL
J Pharmacol Exp Ther; 1998 Jul; 286(1):419-28. PubMed ID: 9655887
[TBL] [Abstract][Full Text] [Related]
19. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference.
Stege A; Priebsch A; Nieth C; Lage H
Cancer Gene Ther; 2004 Nov; 11(11):699-706. PubMed ID: 15375376
[TBL] [Abstract][Full Text] [Related]
20. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
